Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.

• 2025.01.16

  • News Release

  “Bridgea GATEWAY” and “onti” Pass the IHE-J2024 Connectathon Interoperability Test

• 2025.01.10

  • News Release

  LinqMed Announces Series B Funding First close（PeptiDream Inc.）

• 2024.12.27

  • News Release

  Regulatory Approval for Tauvid® ,a PET Imaging Agent

• 2024.12.17

  • Information
  • News Release

  PeptiDream to Construct New Radiotherapeutic/Radiodiagnostic Manufacturing Facility at Kazusa Akademia Park, Chiba

• 2024.12.12

  • News Release

  PDRadiopharma Inc. Releases ‘Report Creation Support Software’ for Amyloid PET scans.

• 2024.12.10

  • News Release

  PeptiDream Announces Upcoming Presentation of Ph0 Human Imaging Study Results for 64Cu-PD-32766, CA9-Targeting PD-32766 Program at ASCO Genitourinary Cancers Symposium

• 2024.12.06

  • News Release

  PDRadiopharma announces listing of Techne® Pyrophosphate Injection on Japan National Health Insurance Drug Price List and Upcoming Market Launch

• 2024.12.05

  • News Release

  NorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement

• 2024.11.20

  • News Release

  Expansion of Insurance Coverage of AMYViD®, a PET Imaging Agent for Detecting Beta Amyloid

• 2024.11.14

  Our Strategic Partner, Curium Announces ECLIPSE Trial has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer（Curiumu）